About PyrAmes & Our Technology


Our Platforms

Presenting Boppli

Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.

Learn More

Presenting Bosimi

Adult inpatient and emergency care cNIBP.

Learn More

Presenting Bosimi@Home

Diagnostics, treatment validation & home medical management.

Learn More

cNIBP Health Impact

PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.

Over 50% of NICU Admissions

could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2

50% of Adults have High BP

50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3

7.6 Million Deaths Annually

Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4

cNIBP & Early Detection

cNIBP has the potential for early detection of conditions within preterm infants and adults.

News & Updates

May 1, 2023

PyrAmes Inc. Announces Investment from March of Dimes to Support Maternal and Pediatric Health Products

CUPERTINO, CA and ARLINGTON, VA — PyrAmes Inc. has received an investment from March of Dimes, the leading organization fighting for the health of moms and babies, to support development and commercialization of its wearable technology to noninvasively monitor blood pressure, particularly for new mothers and their babies. PyrAmes' goal is to develop more convenient, clinically-accurate, blood pressure monitoring for all patients, including both mothers and babies in order to support enhancing their health before and after childbirth. PyrAmes’ Boppli™ device for critically-ill infants received Breakthrough Device Designation from the US Food & Drug Administration (FDA). (more…)

April 27, 2023

International Journal Sensors Highlights PyrAmes’ Technology in Neonatal Clinical Study

PyrAmes’ innovative Boppli™ blood pressure device is featured in the journal Sensors, in a paper reporting a clincal study of 81 infants undergoing critical care at Lucile Packard Children’s Hospital Stanford. Sensors is a leading international, peer-reviewed journal on the science and technology of sensors. The paper, Clinical Study of Continuous Non-Invasive Blood Pressure Monitoring in Neonates, highlights the performance of PyrAmes’ novel algorithm-based blood pressure sensor. Boppli is designed to meet the blood pressure monitoring requirements and physical dimensions of small, prematurely-born infants, without external calibration. Boppli uses machine-learning techniques to extract blood pressure values from the shape of the pulse waveform, and is currently being considered for market clearance by the FDA as a Class II medical device. The paper indicates the use of Boppli is feasible for critically ill term and preterm infants with a wide variety of pathologies—from serious cardiac ailments, pre- and post-operative cases, neurologic conditions, and prematurity.

April 4, 2023

PyrAmes selected for NIH RADx Tech for Maternal Health Challenge final phase

PyrAmes is among only 10 companies chosen to enter the final Technology Assessment phase of the National Institutes of Health (NIH) RADx Tech for Maternal Health Challenge. The goal of the RADx Challenge is to improve maternal health outcomes for those who live in areas lacking access to maternity care through innovative promising home-based or point-of-care diagnostic devices, wearables, and other remote sensing technologies. PyrAmes’ submission, Non-invasive, Continuous Blood Pressure Monitoring for Postpartum Maternal Health, focuses on its Bosimi™ platform, a noninvasive, wearable sensor designed to monitor blood pressure of women in their postpartum period, when the risk of maternal mortality is highest. (more…)

View All News

2020 FDA Breakthrough Device Designation


Founding Member of CDC National Hypertension Control Roundtable


2020 SWPDC Pediatric Device Award, Member of SWPDC


2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator


Exponential Medicine 2019 One to Watch Award